FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 423 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR After Lung Cancer Screening, Follow-Up Procedures May Be Riskier than Thought February 8, 2019 Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with... November 4, 2024 Quality of Life Is Maintained with First-line Nivolumab Plus Ipilimumab in... December 10, 2020 Intratumoural Administration of the Oncolytic Herpes Virus Shows Survival Benefit and... August 18, 2022 Load more HOT NEWS Talking About Your Sexual Orientation and Gender Identity With Your Cancer... Vaping Pods Produce High Nicotine Levels in Young Users New Drug Regimen Cures More Children with Aggressive B-Cell Lymphoma Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab...
